Although these OS data did not meet the authors’ pre-defined threshold of ‘clinically meaningful’—based on historical standards for platinum-doublet chemotherapy—they suggested a potential benefit in the subgroup of patients with a PD-L1 tumor proportion score ≥ 1 who had mOS of 11.0 months (PD-L1 1–49% mOS 11.0 months [95% CI 4.0–16.0], PD-L1 ≥ 50% 11.0 months [95% CI 0–NR]). The gene discussed is CD274; the disease is neoplasm.